Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of dose and response

por Aiken, Robert, Axelson, Magnus, Harmenberg, Johan, Klockare, Maria, Larsson, Olle, Wassberg, Cecilia
Publicado 2017

The Prognostic Value of Pre-Treatment Leukocytosis in Patients with Previously Treated, Stage IIIB/IV Non-Small Cell Lung Cancer Treated with the IGF-1R Pathway Modulator AXL1717 o...

por Holgersson, Georg, Bergqvist, Michael, Nilsson, Jonas, Thureson, Marcus, Harmenberg, Johan, Bergstrom, Stefan
Publicado 2017

Melflufen - a peptidase-potentiated alkylating agent in clinical trials

por Wickström, Malin, Nygren, Peter, Larsson, Rolf, Harmenberg, Johan, Lindberg, Jakob, Sjöberg, Per, Jerling, Markus, Lehmann, Fredrik, Richardson, Paul, Anderson, Kenneth, Chauhan, Dharminder, Gullbo, Joachim
Publicado 2017

Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long‐term survival follow‐up from the Phase II study O‐12‐M1

por Bringhen, Sara, Voorhees, Peter M., Plesner, Torben, Mellqvist, Ulf‐Henrik, Reeves, Brandi, Sonneveld, Pieter, Byrne, Catriona, Nordström, Eva, Harmenberg, Johan, Obermüller, Jakob, Richardson, Paul G.
Publicado 2021

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma

por Richardson, Paul G., Oriol, Albert, Larocca, Alessandra, Bladé, Joan, Cavo, Michele, Rodriguez-Otero, Paula, Leleu, Xavier, Nadeem, Omar, Hiemenz, John W., Hassoun, Hani, Touzeau, Cyrille, Alegre, Adrián, Paner, Agne, Maisel, Christopher, Mazumder, Amitabha, Raptis, Anastasios, Moreb, Jan S., Anderson, Kenneth C., Laubach, Jacob P., Thuresson, Sara, Thuresson, Marcus, Byrne, Catriona, Harmenberg, Johan, Bakker, Nicolaas A., Mateos, María-Victoria
Publicado 2021